Large variability exists in the management of posterolateral corner injuries in the global surgical community.
Pablo Eduardo Gelber, Justin Drager, Bhargavi Maheshwer...
https://pubmed.ncbi.nlm.nih.gov/32239270/Actively Recruiting
Led by Khyber Medical University Peshawar · Updated on 2026-10-21
172
Participants Needed
1
Research Sites
5 weeks
Total Duration
This research aims to evaluate treatments for children aged 5 to 15 years with transfusion-dependent beta-thalassemia major who have not responded well to thalidomide therapy. The study compares thalidomide alone versus a combination of thalidomide, danazol, and prednisolone to see if the combination reduces blood transfusion needs, increases hemoglobin levels, and is safe. About 172 children will be randomly assigned to one of the two treatment groups and followed for 9 to 12 months. Participants will receive either thalidomide alone, with the dose adjusted every 2 to 4 weeks based on response, or a combination of thalidomide plus danazol and prednisolone. Danazol is taken orally three times daily for 30-day cycles, and prednisolone is given twice daily for 10 days each month. Supportive care with famotidine, folic acid, and vitamin B12 is also provided in the combination group. Both treatments last between 9 and 12 months. During the study, participants will be monitored regularly with assessments at months 1, 3, 6, 9, and the final visit. Researchers will check for transfusion independence, hemoglobin levels, and safety using standard criteria. Secondary outcomes include measuring transfusion burden, blood health improvements, quality of life, and genetic factors related to treatment response. The study involves blood tests, clinical evaluations, and tracking of side effects over the follow-up period.
CONDITIONS
Combination Therapy With Danazol, Prednisolone, and Thalidomide for Thalidomide-Refractory Transfusion-Dependent β-Thalassemia
S
Syeda Nayab Imtiaz, MBBS
G
Gulab Fatima Rani, MBBS
Explore thousands of other clinical trials that might be a better match.
Sign up to get personalized trial recommendations delivered to your inbox.
Already have an account? Log in here
Khyber Medical University Peshawar
Lead Sponsor
Pak International Medical College and Hospital, Peshawar
Collaborating Sponsor
You may qualify if you...
You will not qualify if you...
Duration - 2 to 4 weeks
Participants are screened for eligibility to participate in the trial.
1 visit (in-person)
Duration - 9 to 12 months
Participants receive either thalidomide alone or thalidomide combined with danazol and prednisolone over 9 to 12 months. Dosages are adjusted based on response and tolerance. Supportive care is provided as needed.
Scheduled visits at months 1, 3, 6, 9, and final visit
Study Type
INTERVENTIONAL
Masking
NONE
Allocation
RANDOMIZED
Model
PARALLEL
Primary Purpose
TREATMENT
Number of Arms
2
Have more questions? Get in touch with our team for quick support
Pablo Eduardo Gelber, Justin Drager, Bhargavi Maheshwer...
https://pubmed.ncbi.nlm.nih.gov/32239270/D J Weatherall, J B Clegg
https://pubmed.ncbi.nlm.nih.gov/11545326/Keyvan M Safdari, Curtis Converse, Fanglong Dong...
https://pubmed.ncbi.nlm.nih.gov/35222639/Idir Ouzaid, Solène Florence Kammerer-Jacquet, Zineddine Khene...
https://pubmed.ncbi.nlm.nih.gov/32582758/Rahul Nahar, Weiwei Zhai, Tong Zhang...
https://pubmed.ncbi.nlm.nih.gov/29335443/Michael Zywiel, Kira Ellis, Christian J H Veillette...
https://pubmed.ncbi.nlm.nih.gov/33864442/Xiaoying Hou, Pei Zhang, Hongzhi Du...
https://pubmed.ncbi.nlm.nih.gov/34603035/Jean-Pierre Courpied, Jacques Henri Caton
https://pubmed.ncbi.nlm.nih.gov/21243356/Laura Gómez Montoto, Lucía Arregui, Noemí Medina Sánchez...
https://pubmed.ncbi.nlm.nih.gov/22187670/Jonathan O'Callaghan
https://pubmed.ncbi.nlm.nih.gov/37604864/Khyber Medical University Peshawar
Lead Sponsor
Pak International Medical College and Hospital, Peshawar
Collaborating Sponsor